NEWS: 公告在東京證券交易所JASDAQ標準市場新上市


疼痛治療藥的全球市場 - 上市產品、開發中產品,機會,課題,市場規模,主要企業

Global Pain Therapeutics Market - Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players

出版商 GlobalData 商品編碼 1007882
出版日期 內容資訊 英文 93 Pages
疼痛治療藥的全球市場 - 上市產品、開發中產品,機會,課題,市場規模,主要企業 Global Pain Therapeutics Market - Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players
出版日期: 2021年05月31日內容資訊: 英文 93 Pages





第1章 序文

第2章 摘要整理

第3章 疼痛概要

  • 所謂的疼痛
  • 疼痛的分類
  • 急性疼痛
  • 轉移疼痛
  • 慢性疼痛

第4章 趨勢

  • 產業趨勢

第5章 臨床試驗

  • 臨床試驗的疼痛治療藥
  • 疼痛治療藥的臨床試驗:各地區
  • 疼痛治療藥的臨床試驗:各主要贊助商
  • 臨床試驗的疼痛治療藥 - 課題
  • 臨床試驗的疼痛治療藥 - 機會

第6章 上市產品

  • 已上市的全球疼痛產品
  • NSAID和COX-2抑制劑
  • 類鴉片物質
  • 抗憂鬱症藥、抗痙攣藥

第7章 開發中產品

  • 全球疼痛治療開發中產品
  • β神經生長因子標的
  • 垂體腺苷酸環化酶激活多肽 (PACAP) I型受體標的
  • 神經降壓素受體1標的

第8章 市場分析

  • 混合性疼痛市場分析與預測
  • 神經性疼痛市場分析與預測
  • 傷害性疼痛市場分析與預測
  • 疼痛治療領域的前十名的交易
  • 疼痛治療領域的交易
  • 疼痛治療領域的M&A

第9章 機會,課題,未滿足需求

  • 全球疼痛治療 - 機會
  • 全球疼痛治療 - 課題
  • 全球疼痛治療的未滿足需求 - 差距分析

第10章 主要企業

  • Pfizer
  • Eli Lilly
  • Allergan
  • Teva
  • Viatris
  • Novartis

第11章 附錄


Product Code: GDHCHT278

Pain is a multifaceted disorder that can be classified in a multitude of ways. Pain can be classified based on physiology, intensity, temporal characteristics, type of tissue affected, and syndrome.

Innovation in the pain market over the last decade has been limited to new drug delivery systems, new extended-release formulations, and the repositioning of anticonvulsant and antidepressant therapeutics for difficult-to-treat pain conditions.

Despite the improvements in symptom relief offered by new treatments and delivery systems, the pain market still has significant unmet needs. Opioids remain the most effective modes of treatment. However, because of their abuse potential, they are typically administered for chronic pain conditions.

For the scope of this report, GlobalData will use the time course classification, with the main focus on chronic pain.

This report assesses -

  • Physician perceptions on Pain Therapeutics usage in clinical practice Globally.
  • Global Pain Therapeutics main classes Marketed products and main targets Pipeline products.
  • Opportunities and Challenges
  • Market analysis and Forecast
  • Unmet Needs
  • Key Players

The report combines information obtained from secondary sources and primary research with specialists and physicians.

GlobalData's Global Pain Therapeutics Market Overview report combines primary research from a cross-specialty panel of experts with in-house analyst expertise to provide an assessment of the development landscape.

Key Highlights

  • The Pain Therapeutics Market Is Highly Genericized
  • The Neuropathic Pain Market Is the Most Valuable Segment Within the Pain Indications
  • Innovation in the Pain Market Is Limited to New Drug Delivery Systems and New Formulations
  • The Main Focus for Development in the Pipeline Is Drugs for Neuropathic Pain Indications


Components of the slide deck include primary and secondary research -

  • Quotes from key opinion leaders
  • Summary of Pain Therapeutics product definitions and classifications
  • Overview of key classes of Pain Therapeutics marketed products and key targets for pipeline Pain products
  • Trends in Global Pain Therapeutics market
  • Call-outs of key information and details
  • Insight from GlobalData's specialist healthcare analysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Pain Therapeutics.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Pain Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

  • 1.1. Abbreviations
  • 1.2. Related Reports

2. Executive Summary

  • 2.1. Key Findings

3. Pain Overview

  • 3.1. What is Pain?
  • 3.2. Pain Classification
  • 3.3. Acute Pain
  • 3.4. Transitional Pain
  • 3.5. Chronic Pain

4. Trends

  • 4.1. Industry Trends

5. Clinical Trials

  • 5.1. Pain Therapeutics in Clinical Trials
  • 5.2. Pain Therapeutics Clinical Trials by Region
  • 5.3. Pain Therapeutics Clinical Trials by Leading Sponsors
  • 5.4. Pain Therapeutics in Clinical Trials - Challenges
  • 5.5. Pain Therapeutics in Clinical Trials - Opportunities

6. Marketed Products

  • 6.1. Marketed Global Pain Products
  • 6.2. NSAIDs and COX-2 inhibitors
  • 6.3. Opioids
  • 6.4. Antidepressants and Anticonvulsants

7. Pipeline Products

  • 7.1. Global Pain Therapeutics Pipeline Products
  • 7.2. Beta Nerve Growth Factor Target
  • 7.3. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Type I Receptor Target
  • 7.4. Neurotensin Receptor 1 Target

8. Market Analysis

  • 8.1. Mixed Pain Market Analysis and Forecast
  • 8.2. Neuropathic Pain Market Analysis and Forecast
  • 8.3. Nociceptive Pain Market Analysis and Forecast
  • 8.4. Top 10 Deals in the Pain Therapeutics Space
  • 8.5. H1 2021 Deals in the Pain Therapeutics Space
  • 8.6. H2 2020- H1 2021 Mergers and Acquisitions in the Pain Therapeutics Space

9. Opportunities, Challenges, and Unmet Needs

  • 9.1. Global Pain Therapeutics - Opportunities
  • 9.2. Global Pain Therapeutics - Challenges
  • 9.3. Global Pain Therapeutics Unmet Needs - Gap Analysis

10. Key Players

  • 10.1. Pfizer
  • 10.2. Eli Lilly
  • 10.3. Allergan
  • 10.4. Teva
  • 10.5. Viatris
  • 10.6. Novartis

11. Appendix

  • 11.1. Bibliography
  • 11.2. Primary Research
  • 11.3. About the Authors
  • 11.4. About GlobalData
  • 11.5. Contact Us
  • 11.6. Disclaimer